Therapeutic drug monitoring as a component of personalized medicine: Applications in pediatric drug development

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 138-140

  Momper, J D ^a   Wagner, J A ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE FACTORS; CHILD; CHILD, PRESCHOOL; DECISION TREES; DRUG DISCOVERY; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; INFANT, NEWBORN; PEDIATRICS; PHARMACOGENETICS;

EID: 84893785215     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.227     Document Type: Article

References (5)

1. Sanathanan, L.P. & Peck, C.C. The randomized concentration-controlled trial: An evaluation of its sample size efficiency. Control. Clin. Trials 12, 780-794 (1991).
2. US Food and Drug Administration. In vitro companion diagnostic devices draft guidance. . Accessed 10 July 2013.
3. Young, T.E. Therapeutic drug monitoring-The appropriate use of drug level measurement in the care of the neonate. Clin. Perinatol. 39, 25-31 (2012).
4. US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review for AFINITOR DISPERZ. . Accessed 10 July 2013.
5. Dunne, J. et al. Extrapolation of adult data and other data in pediatric drugdevelopment programs. Pediatrics 128, e1242-e1249 (2011).